Regulation Of Human Dihydropyrimidine Dehydrogenase: Implications in the Pharmacogenetics of 5-FU-based Chemotherapy

• Johnston SJ , RidgeSA, CassidyJ, McLeod HL: Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin. Cancer Res.5(9) , 2566–2570 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson MR , DiasioRB: Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.Adv. Enzyme Regul.41 , 151–157 (2001).
   PubMedGoogle Scholar
• Yong WP , InnocentiF, RatainMJ: The role of pharmacogenetics in cancer therapeutics.Br. J. Clin. Pharmacol.62(1) , 35–46 (2006).
   PubMed Web of Science ®Google Scholar
• Diasio RB , HarrisBE: Clinical pharmacology of 5-fluorouracil.Clin. Pharmacokinet.16(4) , 215–237 (1989).
   PubMed Web of Science ®Google Scholar
• Dobritzsch D , SchneiderG, Schnackerz KD, Lindqvist Y: Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J.20(4) , 650–660 (2001).
   PubMed Web of Science ®Google Scholar
• Mattison LK , SoongR, DiasioRB: Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.Pharmacogenomics3(4) , 485–492 (2002).
   PubMed Web of Science ®Google Scholar
• Diasio RB , JohnsonMR: Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.Clin. Cancer Res.5(10) , 2672–2673 (1999).
   PubMed Web of Science ®Google Scholar
• McLeod HL , SluddenJ, MurrayGI et al.: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br. J. Cancer77(3) , 461–465 (1998).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB , VrekenP, AbelingNG et al.: Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet.104(1) , 1–9 (1999).
   PubMed Web of Science ®Google Scholar
• Largillier R , Etienne-GrimaldiMC, FormentoJL et al.: Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res.12(18) , 5496–5502 (2006).
   PubMed Web of Science ®Google Scholar
• Saif MW , DiasioR: Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?Clin. Colorectal Cancer5(5) , 359–362 (2006).
   PubMed Web of Science ®Google Scholar
• Ezzeldin HH , LeeAM, MattisonLK, Diasio RB: Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res.11(24 Pt 1) , 8699–8705 (2005).
   PubMed Web of Science ®Google Scholar
• Lu ZH , ZhangR, DiasioRB: Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties.Biochem. Pharmacol.46(5) , 945–952 (1993).
   PubMed Web of Science ®Google Scholar
• Lu ZH , ZhangR, DiasioRB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver.J. Biol. Chem.267(24) , 17102–17109 (1992).
   PubMed Web of Science ®Google Scholar
• van K uilenburg AB, Dobritzsch D, Meinsma R et al.: Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem. J.364(Pt 1) , 157–163 (2002).
   PubMed Web of Science ®Google Scholar
• Dobritzsch D , RicagnoS, SchneiderG, SchnackerzKD, LindqvistY: Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer.J. Biol. Chem.277(15) , 13155–13166 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson MR , WangK, TillmannsS, Albin N, Diasio RB: Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res.57(9) , 1660–1663 (1997).
   PubMed Web of Science ®Google Scholar
• Wei X , ElizondoG, SaponeA et al.: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics51(3) , 391–400 (1998).
   PubMed Web of Science ®Google Scholar
• Yokota H , Fernandez-SalgueroP, FuruyaH et al.: cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem.269(37) , 23192–23196 (1994).
   PubMed Web of Science ®Google Scholar
• Takabayashi A , IwataS, KawaiY et al.: Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int. J. Oncol.17(5) , 889–895 (2000).
   PubMed Web of Science ®Google Scholar
• Fujiwara H , TerashimaM, IrinodaT et al.: Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J. Cancer Res.93(12) , 1342–1350 (2002).
   PubMedGoogle Scholar
• Johnson MR , WangK, SmithJB, Heslin MJ, Diasio RB: Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem.278(2) , 175–184 (2000).
   PubMed Web of Science ®Google Scholar
• Shestopal SA , JohnsonMR, DiasioRB: Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter.Biochim. Biophys. Acta1494(1–2) , 162–169 (1999).
   Google Scholar
• Noguchi T , TanimotoK, ShimokuniT et al.: Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin. Cancer Res.10(20) , 7100–7107 (2004).
   PubMed Web of Science ®Google Scholar
• Ukon K , TanimotoK, ShimokuniT et al.: Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells. Cancer Res.65(3) , 1055–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang X , LiL, FourieJ, DavieJR, GuarcelloV, DiasioRB: The role of Sp1 and Sp3 in the constitutive DPYD gene expression.Biochim. Biophys. Acta1759(5) , 247–256 (2006).
   PubMedGoogle Scholar
• Harris BE , SongRL, HeYJ, SoongSJ, DiasioRB: Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy.Biochem. Pharmacol.37(24) , 4759–4762 (1988).
   PubMed Web of Science ®Google Scholar
• Harris BE , SongR, SoongSJ, DiasioRB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.Cancer Res.50(1) , 197–201 (1990).
   PubMed Web of Science ®Google Scholar
• Zhang R , LuZ, LiuT, SoongSJ, DiasioRB: Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy.Cancer Res.53(12) , 2816–2822 (1993).
   PubMed Web of Science ®Google Scholar
• Raida M , KlicheKO, SchwabeW et al.: Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. J. Cancer Res. Clin. Oncol.128(2) , 96–102 (2002).
   PubMed Web of Science ®Google Scholar
• Queener SF , MorrisHP, WeberG: Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas.Cancer Res.31(7) , 1004–1009 (1971).
   PubMed Web of Science ®Google Scholar
• Fujiwaki R , IidaK, NakayamaK et al.: Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase. Virchows Arch.443(5) , 672–677 (2003).
   PubMed Web of Science ®Google Scholar
• Yamada H , FukushimaM, KoizumiK et al.: Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver. Int. J. Oncol.22(2) , 359–364 (2003).
   PubMed Web of Science ®Google Scholar
• Kashima N , UedaM, KanazawaJ: Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells.Cancer Sci.94(9) , 821–825 (2003).
   PubMed Web of Science ®Google Scholar
• Ueda M , KitauraK, KusadaO et al.: Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells. Jpn J. Cancer Res.91(11) , 1185–1191 (2000).
   PubMedGoogle Scholar
• Fujii R , SeshimoA, KameokaS: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.Int. J. Clin. Oncol.8(2) , 72–78 (2003).
   PubMedGoogle Scholar
• Haus E , DumitriuL, NicolauGY, BologaS, Sackett-LundeenL: Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer.Chronobiol. Int.18(4) , 709–727 (2001).
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES , JohnstonSJ, BoyceL et al.: Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int. J. Cancer94(2) , 297–301 (2001).
   PubMed Web of Science ®Google Scholar
• Fujiwaki R , HataK, NakayamaK, FukumotoM, MiyazakiK: Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer.J. Clin. Oncol.18(23) , 3946–3951 (2000).
   PubMed Web of Science ®Google Scholar
• Anan K , MitsuyamaS, TamaeK et al.: Increased dihydropyrimidine dehydrogenase activity in breast cancer. J. Surg. Oncol.82(3) , 174–179 (2003).
   PubMed Web of Science ®Google Scholar
• Fukushima M , MoritaM, IkedaK, NagayamaS: Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.Int. J. Mol. Med.12(6) , 839–844 (2003).
   PubMed Web of Science ®Google Scholar
• Nagakawa T , KayaharaM, OhtaT et al.: Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues. Cancer Invest.18(6) , 516–520 (2000).
   PubMed Web of Science ®Google Scholar
• Lu Z , ZhangR, CarpenterJT, DiasioRB: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.Clin. Cancer Res.4(2) , 325–329 (1998).
   PubMed Web of Science ®Google Scholar
• McLeod HL , SluddenJ, HardySC, Lock RE, Hawksworth GM, Cassidy J: Autoregulation of 5-fluorouracil metabolism. Eur. J. Cancer34(10) , 1623–1627 (1998).
   PubMed Web of Science ®Google Scholar
• Chu S , FerroTJ: Sp1: regulation of gene expression by phosphorylation.Gene348 , 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Fry CJ , FarnhamPJ: Context-dependent transcriptional regulation.J. Biol. Chem.274(42) , 29583–29586 (1999).
   PubMed Web of Science ®Google Scholar
• Dishart D , SchnurN, KlanN et al.: GC-rich sequences in the 5-lipoxygenase gene promoter are required for expression in Mono Mac 6 cells, characterization of a novel Sp1 binding site. Biochim. Biophys. Acta1738(1–3) , 37–47 (2005).
   PubMed Web of Science ®Google Scholar
• Albright SR , TjianR: TAFs revisited: more data reveal new twists and confirm old ideas.Gene242(1–2) , 1–13 (2000).
   PubMed Web of Science ®Google Scholar
• Suske G : The Sp-family of transcription factors.Gene238(2) , 291–300 (1999).
   PubMed Web of Science ®Google Scholar
• Li L , HeS, SunJM, DavieJR: Gene regulation by Sp1 and Sp3.Biochem. Cell Biol.82(4) , 460–471 (2004).
   PubMed Web of Science ®Google Scholar
• Pang RT , LeeLT, NgSS, YungWH, Chow BK: CpG methylation and transcription factors Sp1 and Sp3 regulate the expression of the human secretin receptor gene. Mol. Endocrinol.18(2) , 471–483 (2004).
   PubMedGoogle Scholar
• Wong WK , ChenK, ShihJC: Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation.J. Biol. Chem.278(38) , 36227–36235 (2003).
   PubMed Web of Science ®Google Scholar
• Chadjichristos C , GhayorC, HerrouinJF et al.: Down-regulation of human type II collagen gene expression by transforming growth factor-β 1 (TGF-β 1) in articular chondrocytes involves SP3/SP1 ratio. J. Biol. Chem.277(46) , 43903–43917 (2002).
   PubMed Web of Science ®Google Scholar
• Hata Y , DuhE, ZhangK, RobinsonGS, AielloLP: Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence.J. Biol. Chem.273(30) , 19294–19303 (1998).
   PubMed Web of Science ®Google Scholar
• Apt D , WattsRM, SuskeG, BernardHU: High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter.Virology224(1) , 281–291 (1996).
   PubMed Web of Science ®Google Scholar
• Safe S , AbdelrahimM: Sp transcription factor family and its role in cancer.Eur. J. Cancer41(16) , 2438–2448 (2005).
   PubMed Web of Science ®Google Scholar
• Abdelrahim M , SmithR 3rd, Burghardt R, Safe S: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res.64(18) , 6740–6749 (2004).
   PubMed Web of Science ®Google Scholar
• Klose RJ , BirdAP: Genomic DNA methylation: the mark and its mediators.Trends Biochem. Sci.31(2) , 89–97 (2006).
   PubMed Web of Science ®Google Scholar
• Jain PK : Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes.Ann. NY Acad. Sci.983 , 71–83 (2003).
   PubMed Web of Science ®Google Scholar
• Momparler RL : Cancer epigenetics.Oncogene22(42) , 6479–6483 (2003).
   PubMed Web of Science ®Google Scholar
• Goffin J , EisenhauerE: DNA methyltransferase inhibitors-state of the art.Ann. Oncol.13(11) , 1699–1716 (2002).
   PubMed Web of Science ®Google Scholar
• Baylin SB , OhmJE: Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nat. Rev. Cancer6(2) , 107–116 (2006).
   PubMed Web of Science ®Google Scholar
• Jubb AM , QuirkeP, OatesAJ: DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility.Ann. NY Acad. Sci.983 , 251–267 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang X , SoongR, WangK et al.: Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of DPYD promoter; a potentially important epigenetic mechanism regulating DPYD expression. Biochem. Cell Biol. (2007) (In Press).
   Google Scholar
• Yu J , McLeodHL, EzzeldinHH, Diasio RB: Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin. Cancer Res.12(12) , 3864 (2006).
   PubMedGoogle Scholar
• Zhu WG , SrinivasanK, DaiZ et al.: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol. Cell Biol.23(12) , 4056–4065 (2003).
   PubMed Web of Science ®Google Scholar
• Ohtani-Fujita N , FujitaT, AoikeA, OsifchinNE, RobbinsPD, SakaiT: CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene.Oncogene8(4) , 1063–1067 (1993).
   PubMed Web of Science ®Google Scholar
• Zhang Z , HuettnerPC, NguyenL et al.: Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene25(39) , 5436–5445 (2006).
   PubMed Web of Science ®Google Scholar
• Mancini DN , SinghSM, ArcherTK, RodenhiserDI: Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB, SP1 transcription factors.Oncogene18(28) , 4108–4119 (1999).
   PubMed Web of Science ®Google Scholar
• Knoepfler PS , EisenmanRN: Sin meets NuRD and other tails of repression.Cell99(5) , 447–450 (1999).
   PubMed Web of Science ®Google Scholar
• Cameron EE , BachmanKE, MyohanenS, HermanJG, BaylinSB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.Nat. Genet.21(1) , 103–107 (1999).
   PubMed Web of Science ®Google Scholar
• Shaw RJ , LiloglouT, RogersSN et al.: Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br. J. Cancer.94(4) , 561–568 (2006).
   PubMed Web of Science ®Google Scholar
• Hasegawa T , KimHS, FukushimaM, WatayaY: Sequence analysis of the 5´-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil.Nucleosides Nucleotides Nucleic Acids24(4) , 233–242 (2005).
   PubMed Web of Science ®Google Scholar
• Saif MW , EzzeldinH, VanceK, SellersS, DiasioRB: DPYD*2A mutation: the most common mutation associated with DPD deficiency.Cancer Chemother. Pharmacol. (2006) (In Press).
   Web of Science ®Google Scholar
• Sadee W , DaiZ: Pharmacogenetics/genomics and personalized medicine.Hum. Mol. Genet.14 , R207–R214 (2005).
   PubMed Web of Science ®Google Scholar
• Trakooljul N , PonsuksiliS, SchellanderK, WimmersK: Polymorphisms of the porcine androgen receptor gene affecting its amino acid sequence and expression level.Biochim. Biophys. Acta1678(2–3) , 94–101 (2004).
   PubMedGoogle Scholar
• Schulz S , SchagdarsurenginU, GreiserP et al.: The LDL receptor-related protein (LRP1/A2MR) and coronary atherosclerosis--novel genomic variants and functional consequences. Hum. Mutat.20(5) , 404 (2002).
   PubMedGoogle Scholar
• Curran JE , JowettJB, ElliottKS et al.: Genetic variation in selenoprotein S influences inflammatory response. Nat. Genet.37(11) , 1234–1241 (2005).
   PubMed Web of Science ®Google Scholar
• LeVan TD , BloomJW, BaileyTJ et al.: A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J. Immunol.167(10) , 5838–5844 (2001).
   PubMed Web of Science ®Google Scholar

Website

• University of California Santa Cruz Genome Bioinformatics. http://genome.ucsc.edu/.
   Google Scholar